JP2017502961A - グルコセレブロシダーゼモジュレーターおよびその使用 - Google Patents

グルコセレブロシダーゼモジュレーターおよびその使用 Download PDF

Info

Publication number
JP2017502961A
JP2017502961A JP2016543197A JP2016543197A JP2017502961A JP 2017502961 A JP2017502961 A JP 2017502961A JP 2016543197 A JP2016543197 A JP 2016543197A JP 2016543197 A JP2016543197 A JP 2016543197A JP 2017502961 A JP2017502961 A JP 2017502961A
Authority
JP
Japan
Prior art keywords
gcase
azaspiro
octane
diol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016543197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502961A5 (enExample
Inventor
ラメシュ カウル
ラメシュ カウル
アーネスト ジェイ マッキーチャン
アーネスト ジェイ マッキーチャン
ジャンユ スン
ジャンユ スン
デイヴィッド ジェイ ヴォカドロ
デイヴィッド ジェイ ヴォカドロ
ユアンシー ジョウ
ユアンシー ジョウ
ヨンバオ ジュー
ヨンバオ ジュー
Original Assignee
アレクトス セラピューティックス インコーポレイテッド
アレクトス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクトス セラピューティックス インコーポレイテッド, アレクトス セラピューティックス インコーポレイテッド filed Critical アレクトス セラピューティックス インコーポレイテッド
Publication of JP2017502961A publication Critical patent/JP2017502961A/ja
Publication of JP2017502961A5 publication Critical patent/JP2017502961A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2016543197A 2013-12-23 2014-12-22 グルコセレブロシダーゼモジュレーターおよびその使用 Pending JP2017502961A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361920160P 2013-12-23 2013-12-23
US61/920,160 2013-12-23
US201462005196P 2014-05-30 2014-05-30
US62/005,196 2014-05-30
PCT/CA2014/051252 WO2015095963A1 (en) 2013-12-23 2014-12-22 Glucocerebrosidase modulators and uses thereof

Publications (2)

Publication Number Publication Date
JP2017502961A true JP2017502961A (ja) 2017-01-26
JP2017502961A5 JP2017502961A5 (enExample) 2018-02-08

Family

ID=53477250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016543197A Pending JP2017502961A (ja) 2013-12-23 2014-12-22 グルコセレブロシダーゼモジュレーターおよびその使用

Country Status (4)

Country Link
US (2) US9796680B2 (enExample)
EP (1) EP3087056A4 (enExample)
JP (1) JP2017502961A (enExample)
WO (1) WO2015095963A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021501135A (ja) * 2017-10-26 2021-01-14 シャイア ヒューマン ジェネティック セラピーズ インコーポレイテッド グルコセレブロシダーゼ及びイソファゴミンを含む製剤
JP2022530017A (ja) * 2019-04-25 2022-06-27 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105631432B (zh) * 2016-01-04 2020-12-08 京东方科技集团股份有限公司 指纹探测电路及驱动方法和显示装置
US11001891B2 (en) 2016-11-14 2021-05-11 Berg Llc Methods for treating Parkinson's disease
CN108530375B (zh) * 2018-05-29 2020-04-21 南京药石科技股份有限公司 4-氧杂-7-氮杂螺[2.5]辛烷或其盐的中间体及制备方法
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US12331022B2 (en) 2019-05-02 2025-06-17 Merck Sharp & Dohme Llc Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
KR20240016286A (ko) * 2021-04-30 2024-02-06 밴쿠아 바이오, 인크. 글루코세레브로시다아제 활성의 저분자 조절제 및 이의 용도
CA3218259A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
CA3235270A1 (en) * 2021-10-13 2023-04-20 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512253A (ja) * 2003-11-12 2007-05-17 アミカス セラピューティックス インコーポレイテッド ゴーシェ病を治療するための、ヒドロキシピペリジン誘導体
JP2008523145A (ja) * 2004-12-13 2008-07-03 イーライ リリー アンド カンパニー リポキシゲナーゼ阻害剤としてのスピロ誘導体
WO2012058193A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
JP2013508366A (ja) * 2009-10-19 2013-03-07 アミカス セラピューティックス インコーポレイテッド 中枢神経系の変性障害を予防および／または治療するための新規の組成物
WO2013075227A1 (en) * 2011-11-25 2013-05-30 The Hospital For Sick Children β-GLUCOCEREBROSIDASE CHAPERONES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2040548T3 (da) 2006-06-23 2012-08-13 Amicus Therapeutics Inc Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
CA2758187C (en) 2009-04-09 2017-03-07 Robert Boyd Methods for preventing and/or treating degenerative disorders of the central nervous system
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
MX354127B (es) 2012-03-27 2018-02-14 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512253A (ja) * 2003-11-12 2007-05-17 アミカス セラピューティックス インコーポレイテッド ゴーシェ病を治療するための、ヒドロキシピペリジン誘導体
JP2008523145A (ja) * 2004-12-13 2008-07-03 イーライ リリー アンド カンパニー リポキシゲナーゼ阻害剤としてのスピロ誘導体
JP2013508366A (ja) * 2009-10-19 2013-03-07 アミカス セラピューティックス インコーポレイテッド 中枢神経系の変性障害を予防および／または治療するための新規の組成物
WO2012058193A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
WO2013075227A1 (en) * 2011-11-25 2013-05-30 The Hospital For Sick Children β-GLUCOCEREBROSIDASE CHAPERONES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEARSON, M. S. M. ET AL.: "The spirocyclopropyl moiety as a methyl surrogate in the structure of L-fucosidase and L-rhamnosidas", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 17(23), JPN6018039896, 2009, pages 8020 - 8026, ISSN: 0003896053 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021501135A (ja) * 2017-10-26 2021-01-14 シャイア ヒューマン ジェネティック セラピーズ インコーポレイテッド グルコセレブロシダーゼ及びイソファゴミンを含む製剤
JP2022530017A (ja) * 2019-04-25 2022-06-27 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤
JP7642561B2 (ja) 2019-04-25 2025-03-10 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤
JP2025084834A (ja) * 2019-04-25 2025-06-03 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Also Published As

Publication number Publication date
US10081601B2 (en) 2018-09-25
EP3087056A1 (en) 2016-11-02
US9796680B2 (en) 2017-10-24
US20180009761A1 (en) 2018-01-11
EP3087056A4 (en) 2017-07-19
US20170029379A1 (en) 2017-02-02
WO2015095963A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
US10081601B2 (en) Glucocerebrosidase modulators and uses thereof
US11802122B2 (en) 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
ES3053484T3 (en) Cyclopropyl dihydroquinoline sulfonamide compounds
ES2390937T3 (es) Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1
US20220380338A1 (en) Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
US20240246932A1 (en) Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
EP3828174A1 (en) Pyridazinone derivative
EA032443B1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
RU2521286C2 (ru) Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани
JP7594548B2 (ja) 非リソソームグルコシルセラミダーゼ阻害剤及びその使用
CN115803025B (zh) 非溶酶体葡糖神经酰胺酶抑制剂及其用途
EP3858813A1 (en) Quinolone derivative having indoleamine-2,3-dioxygenase inhibited activity
JP7674389B2 (ja) 非リソソームグルコシルセラミダーゼ阻害剤及びその使用
CN111253412A (zh) α-倒捻子素衍生物及其应用
TWI879947B (zh) 取代的氮雜五元環類化合物及其在藥物中的應用
WO2025019454A2 (en) Substituted ergolines
HK40053244A (en) Pyridazinone derivative
HK40011011A (en) Cannabinoid receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190516